38 results about "Immunocompatibility" patented technology

Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

A system and method to predict and assess immunogenicity, especially prior to on-set of immunogenic conditions. Also disclosed are methods to identify relevant peptides associated with the formation of antibodies in patients treated with a given protein therapeutic. In various aspects, the present application is directed to methods of determining the immunological compatibility of a subject with a therapeutic agent such as a proteinaceous therapeutic agent, methods of determining vaccine efficacy by determining the immunological compatibility of a subject with a therapeutic agent, and selecting a therapeutic agent for a subject in need of treatment. Methods of designing a therapeutic agent with reduced immunogenicity for a subject and methods for designing vaccines with enhanced immunogenicity for a subject are also contemplated.

Provided herein is a placental membrane product comprising an immunocompatible amniotic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing and tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, inhibiting proteases and free radical oxidation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to prevent adhesions, to exclude bacteria, to inhibit bacterial activity, and/or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.

This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning. Also encompassed are methods for determining the effect on immune compatibility of expressed transgenes and other genetic manipulations of the engineered cells and tissues.

Provided herein is a placental membrane product comprising an immunocompatible chorionic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing or tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to exclude bacteria, to inhibit bacterial activity, or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.

The invention discloses a method for preparing biomimetic artificial bone materials for biodegradable tissue engineering. The method comprises the following steps: adding a hydroxyapatite suspension to a human-like collagen solution; adding Genipin for crosslinking; performing vacuum freeze-drying to obtain human-like collagen/ hydroxyapatite powder; adding the human-like collagen/ hydroxyapatite powder to a chitosan solution; using an NaOH solution to adjust the pH of the solution to 7.0; repeatedly adding the human-like collagen solution and the chitosan solution; adding a Genipin solution for crosslinking; freeze-drying a mixed solution; inoculating the obtained material with BMSCs of which the cell density is 5*104 cells/cm2; performing culture for 1 to 10 days; using an induction medium to culture BMSCs cells so as to induce the BMSCs cells to differentiate towards an osteogenesis direction; and forming bone repair composite materials with bone inducing activity. The artificial bone materials prepared by the method are excellent in bone inducing activity and immune compatibility, thereby thoroughly putting an end to inevitable viral hidden trouble of animal collagen scaffold materials and greatly improving use safety.

The invention discloses a method for preparing a biodegradable blood vessel external scaffold material used in tissue engineering, comprising the steps as follows: using distilled water to dissolve human-like collagen to be a 1%-3% solution; using diluted acid to dissolve chitosan to be a 0.5%-1.5% solution; mixing the two solutions evenly, adding aqueous glutaric dialdehyde solution with the concentration of 20-50% according to mass percentage, mixing and stirring, and filtering followed by vacuum de-foaming; pouring the mixed solution into a tube-shaped die, cross-bonding at 4 DEG C for 1-3 days, placing the same into a refrigerator with the temperature being negative 80 DEG C for refrigerating, and then drying to obtain the blood vessel external scaffold material. Compared with the prior art, the prepared scaffold material has excellent mechanicalness, bio-compatibility, blood compatibility and immunity compatibility, is much lower in immunological rejection response, and can eradicate the potential virus hazard which can not be avoided by animal collagen, causing the security to be improved vastly.

The invention discloses a skin repairing liquid and a preparation method thereof and belongs to the technical field of skin repairing. The skin repairing liquid is a conditional culture liquid derivedfrom umbilical cord mesenchymal stem cells. Compared with a method that mesenchymal stem cells are directly applied to treatment on skin wounds, the skin repairing liquid disclosed by the invention avoids security problems related to living cell transplanting and cell proliferation, such as immune compatibility, tumorigenicity and propagation of infectious diseases; in addition, security, dosagesand effects of components in a conditional culture medium can be evaluated by using a method similar to a method for evaluating conventional medicines; the skin repairing liquid disclosed by the invention is easy to produce and prepare, can be subjected to freeze drying preservation, is easy to package and transport, does not take the time for anabiosis, stem cell proliferation and the like before treatment, and is convenient to use.

The present invention relates to a method for producing immune-compatible cells or a cell population which comprises a step of editing one or two alleles of one or more immune-compatible antigen genes by gene deletion or modification in an isolated cell comprising at least one of the immune-compatible antigen genes selected from HLA (human leukocyte antigen)-A, HLA-B and HLA-DR, to immune-compatible cells produced by the method, and to a cell population comprising the immune-compatible cells produced by the method

Methods are provided for preventing or attenuating pathoangiogenic conditions by administering at least one GBS toxin receptor polypeptide or at least one immunogenic fragment thereof. Also provided are a composition that includes a GBS toxin receptor polypeptide and a method for making such a composition. In another embodiment of the invention, immunized animals also receive GBS toxin, immunocompatible antibodies to the GBS toxin receptor, and/or expanded autologous T cells to the GBS toxin receptor. Also included in this invention are methods of identifying additional GBS toxin receptors.

The invention discloses immunocompatible reversible universal pluripotent stem cells or derivatives thereof. An inducible gene expression system and an expression sequence of at least one immunocompatible molecule are introduced into the genome of the pluripotent stem cells or the derivatives thereof. The immunocompatible molecules are used for regulating and controlling the expression of genes related to immune response in pluripotent stem cells or derivatives of the pluripotent stem cells. The expression of the immunocompatible molecule is regulated and controlled by an inducible gene expression system. According to the technical scheme, the immunocompatibility between the graft and the receptor can be improved, and the antigen presentation capability of graft cells can be reversibly recovered, so that the clinical safety of such universal pluripotent stem cells and derivatives is improved, and the clinical application value of the universal pluripotent stem cells and derivatives isgreatly expanded.

Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals.

A polymer matrix is provided comprising an amine-containing polyampholyte covalently crosslinked with an electrophilic polymer to yield an immunocompatible polymer matrix. A hydrogel system incorporating the polymer matrix is also provided.

The invention relates to a stem cell film-forming culture medium and application thereof, the stem cell film-forming culture medium comprises a cell basal culture medium, fetal calf serum, growth factors, an attachment skeleton material and vitamins, and the method relates to preparation of the stem cell film-forming culture medium, separation of stem cells, culture of the stem cells and stem cell film formation. The method has the beneficial effects that the collagen is subjected to low-temperature centrifugal membrane forming by utilizing the dissolving property of the collagen, so that the operation cost and the technical requirements are low, and large-scale production is facilitated; the finally obtained stem cell biological patch is high in immunocompatibility, few in adverse reaction and thin in membrane thickness, the thickness can be controlled according to the temperature and the centrifugal time, the stem cells are embedded into the biological patch membrane, the stem cells are slowly released along with absorption of a matrix by a body after transplantation, and therefore the effect taking time is longer, and the survival rate of the stem cells is increased. Compared with a stem cell biological patch prepared by common culture and adsorption, the stem cell biological patch has a better ovary repairing effect.

The invention provides for the use of an improved xenograft bone particulate with respect to osteo-integration and bone remodeling, while diminishing the primate-to-pig immunological response using established bone-processing technique. Work was carried out using undecalcified bone to determine immunocompatibilty and bone remodeling potential of processed porcine bone struts following onlay graft implantation. New bone formation was evident, including the infiltration of cellular materials responsible for fusion and bone reconstruction.

The present invention relates to methods for preparing immunocompatible tissues and cells for transplantation and tissue engineering purposes, using nuclear transfer and cloning techniques. The invention also includes methods by which the effect of expressed transgenes and other genetic manipulations on the immunocompatibility of engineered cells and tissues can be determined.

The present disclosure relates to a method for inducing pluripotent stem cells by inducing reprogramming and/or dedifferentiation of differentiated adult cells using shikimic acid, a plant extract or plant stem cells containing shikimic acid and an extract of dedifferentiated stem cells (callus), pluripotent stem cells prepared by the method and a composition containing the pluripotent stem cells. In accordance with the present disclosure, ethical concerns implicated with the use of eggs to prepare pluripotent stem cells such as embryonic stem cell can be resolved. And, because the plant stem cell extract unharmful to human is used, pluripotent stem cells with proven safety can be prepared and they may be used to develop immunocompatible cell therapy agents suited for individuals. In addition, by pluripotent stem cells from individuals having diseases, the present disclosure will be very useful in studying the cause of diseases and devolving therapeutic strategy.